Why Influencers Use the FDA to Bash Research Peptides

The FDA's drug review budget does not come from taxpayers. It comes from the companies whose drugs are being reviewed.

This is called PDUFA, the Prescription Drug User Fee Act, which is a system where pharmaceutical companies pay a fee to have their drug application reviewed by the FDA. In fiscal year 2024, that fee was $4,198,000 per application. Those fees now fund approximately 65% of the FDA's entire human drug review budget at CDER and CBER, the two centers responsible for approving the drugs your doctor prescribes.

So the entity being regulated is the primary funder of its own regulator. That is not a conspiracy theory. That is the published budget structure of the agency.

Now layer in what happens when FDA officials leave. A 2018 analysis published in Science found that 62% of FDA medical officers who left the agency between 2006 and 2019 went directly to work for the pharmaceutical industry. Scott Gottlieb served as FDA Commissioner from 2017 to 2019 and joined Pfizer's board of directors the same year he left. The pathway from regulator to regulated is not an exception. It is the norm.

And outside the agency, the pharmaceutical and health products industry spent $374 million on federal lobbying in 2023, making it the single highest-spending industry in Washington, with roughly three registered lobbyists for every one member of Congress.

This is the regulatory framework that certain influencers and podcast personalities point to when they argue that research peptides are unsafe.

Here is why that argument does not hold up structurally.

Most research peptides are sequences that occur naturally in the human body or in food sources. Because they are naturally occurring, they cannot be patented. Because they cannot be patented, no pharmaceutical company can bring one to market and then legally prevent competitors from copying the molecule. A 2020 analysis in JAMA Internal Medicine found the median capitalized cost of bringing a new drug through FDA approval between 2009 and 2018 was $985 million. No company will spend that to approve a molecule that any competitor can immediately replicate without paying for the decade of research behind it.

This means research peptides will not carry FDA approval not because they are inherently dangerous, but because there is no financial pathway that makes approval rational for any private company operating in the current system.

That is not a safety determination. It is a market structure problem.

So when someone uses FDA approval as a proxy for safety and the absence of it as a proxy for danger, they are either misunderstanding how approval works or they understand it exactly and are using the misunderstanding of their audience to their advantage.

The second case is worth examining carefully, because there is a business model that sits just on the other side of this argument.

Compounding pharmacies can produce peptides legally for patient use when a licensed prescriber orders them. Some influencers who argue loudly against research chemicals are simultaneously selling access to peptides through compounding pharmacy channels, which require a consultation fee, a prescription markup, and often a recurring relationship with a provider in their ecosystem. The product is functionally the same molecule. The revenue structure is dramatically different.

Using the FDA's authority to discredit one channel while profiting from an adjacent channel that sidesteps the same authority is not a principled safety position. It is a market positioning strategy dressed in the language of regulation.

The deeper problem is that the FDA's credibility is not uniform across categories. The same agency that provides the approval framework being cited has also approved opioids that generated mass addiction, allowed food additives that are banned across much of Europe, and authorized COVID countermeasures under emergency pathways that bypassed standard evidentiary requirements. Treating FDA approval as a binary signal for safety and non-approval as a binary signal for danger ignores the documented history of what that approval process has and has not protected people from.

If you are thinking about whether a research peptide is safe to use, the right questions are about the actual evidence on that specific compound, the quality and purity of the source, the dosing data that exists, and the risks specific to your health context. Those are real questions worth working through.

The FDA approval status of the molecule tells you primarily whether a pharmaceutical company found it profitable enough to push through a billion-dollar regulatory process, and that is a question about corporate economics, not about your body.

The person using government capture to sell you something is not the person who gets to claim they are protecting you from it.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness